Literature DB >> 1399946

In-vitro antibacterial activity of RP 59500, a semisynthetic streptogramin, against Streptococcus pneumoniae.

A Fremaux1, G Sissia, R Cohen, P Geslin.   

Abstract

The in-vitro activity of the new streptogramin RP 59500 was determined against 100 strains of Streptococcus pneumoniae. In all, 48 erythromycin-sensitive strains and 52 erythromycin-resistant strains were tested by an agar dilution method (MIC determination), 20 strains (eight erythromycin-sensitive and 12 erythromycin-resistant) were tested by a broth microdilution technique (MIC and MBC determination) and ten strains (two erythromycin-sensitive and eight erythromycin-resistant) were tested for bactericidal kinetics. The study showed that RP 59500 had good bacteristatic and bactericidal activity against both erythromycin-sensitive and erythromycin-resistant strains. On the basis of these results, and because the number of erythromycin-resistant strains of S. pneumoniae isolated in France has increased steadily since 1985, RP 59500 might be useful for the treatment of pneumococcal infections and warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399946     DOI: 10.1093/jac/30.suppl_a.19

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 2.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 3.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

4.  Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 5.  Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.

Authors:  R G Finch
Journal:  Drugs       Date:  1996       Impact factor: 9.546

6.  Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

Authors:  F Caron; H S Gold; C B Wennersten; M G Farris; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

7.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.

Authors:  R R Reinert; M Kresken; V Mechery; M Lemperle; R Lütticken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.